GLP-1 Market
LLY $1184.63 ▼ -0.0% NVO $38.31 ▼ -1.0% PFE $28.72 • 0.0% VKTX $31.81 ▼ -3.7% KLRA $10.99 ▼ -1.2% GPCR $32.69 ▼ -6.8% RHHBY $52.25 ▼ -2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

RAPA-501 Autologous T stem cells

RAPA-501 Autologous T stem cells

Company
Rapa Therapeutics LLC
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 30, 2026

Find a Clinical Trial Near Me

See recruiting studies for RAPA-501 Autologous T stem cells and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04220190

    RAPA-501 Therapy for ALS

    Not yet reported, Not yet reported Rapa Therapeutics LLC 41 participants Est. completion 2028-07-01 1 site Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Terminated NCT NCT04482699

    RAPA-501-Allo Therapy of COVID-19-ARDS

    Not yet reported, Not yet reported Rapa Therapeutics LLC 1 participants Est. completion 2021-09-13 1 site Stand-alone
    Other conditions: Severe COVID-19 Disease
    View official trial listing →
  • Temporarily Not Available NCT NCT06169176

    RAPA-501 Therapy of ALS Expanded Access Protocol

    Rapa Therapeutics LLC 10 sites
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: RAPA-501 Autologous T stem cells, RAPA-501 cells

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.